Immutep Limited American Depositary Shares (IMMP) Stock Price

IMMPStock
$3.20−92.33%52W
Market Cap$23.58M
P/E—
PEG Ratio—
Div yield—
Beta2.10

IMMP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-76.57%
Price vs S&P 500 (4W)-41.17%
VGM Score63.57

IMMP Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.63
3.63
3.63
3.63

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
IMMPImmutep Limited American Depositary Shares
AAF2.3x24185.4%——$3.20
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Immutep Limited American Depositary Shares

Immutep is a Phase 3 clinical-stage biotechnology company developing LAG-3 immunotherapies to treat cancer and autoimmune diseases. Its lead candidate, eftilagimod alfa (efti), is in a registrational Phase 3 trial for first-line non-small cell lung cancer. The company's diversified pipeline includes additional LAG-3-based programs targeting various solid tumors and autoimmune indications.